- Momenta Pharma present 6/6/11 at the Jefferies conference (webcast link can be found on Upcoming Events page). Check out the MNTA research page for additional info and link.
- Here are my notes (nothing really new presented today by CFO Rick Shea):
- MNTA is "the only one truly trying to make equivalent biogenerics"
- MNTA believes that interchangable status is the only way to differentiate follow-on biologic products and is the only way anyone will make any money in this business
- M118- energineered for ACS market, which is not well served now w/ products including low molecular weight heparins (LMWH) including lovenox, angiomax, and heparins
- "continuing discussions for potential partnership" for M118
- M402- antitumor properites of heparins w/o anticoagulant activity
- M402 IND and into clinic in 2011 (this has definitely slipped now form prior statements of IND around mid-year 2011)
- no webcast q&a
RSS Feed
